HC Wayne Wright Hepatitis B Virus (HBV) VBI Vaccine Presented at Mini Conference | Business

Cambridge, Massachusetts-(BUSINESSWIRE)-October 15, 2020-

VBIVaccines Inc. (Nasdaq: VBIV) (VBI), a commercial biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today has management team members VBI as candidates for our vaccine immunotherapy. -Announced to discuss 2601. Features of hepatitis B (HBV) infection in a chat by the fireplace at the HC Wayne Wright Hepatitis B Virus (HBV) mini-conference held on Tuesday, October 20, 2020 at 2:00 pm (Eastern Time) Under development of therapeutic method.

Presentation details

Event: HC Wayne Wright HBV Mini Conference – Virtual

Presenter: Jeff Baxter, President and CEO of VBI, and Dr. David E. Anderson, Chief Scientific Officer of VBI

date: Tuesday, October 20, 2020

time: 2: 00-2: 30 PM ET

Web cast: https://journey.ct.events/view/0a5ed8a2-b6b8-43d8-b016-0f1b4c5e7e05

Webcast records are available on the Events / Presentations page of the Investors section of the VBI website.

About hepatitis B

Hepatitis B is one of the most serious infectious disease threats in the world, affecting more than 290 million people worldwide. HBV infection is a major cause of liver disease and many patients continue to develop liver cancer or cirrhosis because there is no cure available. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma.

VBI Vaccines Inc.about

VBI Vaccine Co., Ltd. ((( NASDAQ: VBIV ) Is a commercial biopharmacy company developing next-generation vaccines to address unmet needs in infectious diseases and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B as follows. (1) The only three-antigen hepatitis B vaccine, Sci-B-Vac®, has been approved for use in Israel and is commercially available, and has recently completed the Phase 3 program. United States, Europe, and Canada. (2) Immunotherapy under development of a functional treatment for chronic hepatitis B. VBI’s Envelope Virus-like Particle (eVLP) platform technology enables the development of eVLP that closely mimics the target virus and elicits a strong immune response. VBI’s key eVLP programs include vaccine immunotherapy candidates targeting glioblastoma (GBM), prophylactic cytomegalovirus (CMV) vaccine candidates, and prophylactic pan-coronavirus vaccine candidates. Headquartered in Cambridge, Massachusetts, VBI has research activities in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

Website Home: http://www.vbivaccines.com/

News and insights: http://www.vbivaccines.com/wire/

Investor: http://www.vbivaccines.com/investors/

Precautions regarding future prospects

The specific statements in this press release are forward-looking statements, not historical facts, and forward-looking statements in the sense of the Safe Harbor clause of the Private Securities Litigation Reform Act of 1995, and the future in the Canadian sense. Information about the outlook for. Securities Law (collectively, “statement of future prospects”). We note that such statements include risks and uncertainties that may have a significant impact on our performance. These forward-looking statements are based on management’s beliefs, as well as assumptions made by management and information currently available to management. Actual results are not expected in forward-looking statements as a result of certain factors, including but not limited to the effects of general economic, industrial, or political conditions in the United States or internationally. It can be very different. The impact of the ongoing COVID-19 pandemic on clinical trials, manufacturing, business planning, and the global economy. Ability to prove that a potential product is effective or safe in preclinical or clinical trials. Ability to establish or maintain collaboration on the development of therapeutic drug candidates. Ability to obtain appropriate or necessary government approval to sell potential products. Ability to obtain future funding for development products and working capital, and to obtain such funding on commercially reasonable terms. Our ability to manufacture product candidates on a commercial scale or in collaboration with third parties. Changes in the size and nature of competitors. Ability to retain key executives and scientists. Ability to secure and enforce legal rights related to our products. A discussion of these and other factors, including risks and uncertainties regarding us, is our filing with the SEC and the Canadian Securities Authority, including the Form 10-K Annual Report filed with the SEC on March 5. It is described in. Submitted to Canadian security authorities in 2020 sedar.com May 5, 2020, supplemented or amended by the company’s quarterly report on Form 10-Q. Considering these risks, uncertainties, and factors, please be careful not to overly rely on such forward-looking statements that are fully qualified by this warning statement. All such forward-looking statements contained in this document are based on our current expectations and, for whatever reason, forward-looking statements, except as required by law. You have no obligation or obligation to update or revise.

View source version above businesswire.com:https://www.businesswire.com/news/home/20201015005235/en/

Contact: VBI

Nicole Anderson

Corporate Communication & IR Director

Phone number: (617) 830-3031 x124

Email: [email protected]

Keywords: United States North America Massachusetts

Industry Keywords: Infectious Disease Research FDA Clinical Trials Biotechnology Pharmaceutical Health Sciences Oncology Other Sciences

Source: VBI Vaccines Inc.

Copyright Business Wire 2020.

PUB: 10/15/2020 08: 00 AM / DISC: 10/15/2020 08:01 AM

http://www.businesswire.com/news/home/20201015005235/en

Copyright Business Wire 2020.